VANI240517P1000
- 0.05
- 0.000.00%
Vivani Medical Newsroom
Buy Rating Justified: Vivani Medical's Promising NPM-115 Implant and Strategic Market Positioning
10-Q: Quarterly report
Vivani Medical Shares Operational Updates at Conferences
Express News | Vivani Medical Inc - Qtrly Shr Loss $0.12
Express News | Vivani Medical Inc - Stable Financial Position Supports Operations Into Second Half of 2025
Express News | Vivani Medical Inc - Continues Advancing Development of Miniature, Long-Term GLP-1 Implants
Vivani Medical 1Q Loss/Shr 12c >VANI
Vivani Medical 1Q Loss/Shr 12c >VANI
Press Release: Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chroni
Express News | Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
Express News | Vivani Medical Q1 Income From Operations USD -6.227 Million
Express News | Vivani Medical Q1 Net Income USD -6.039 Million
Express News | Vivani Medical Q1 Basic EPS USD -0.12
Express News | Vivani Medical Q1 Operating Expenses USD 6.227 Million
Express News | Vivani Medical- Sales Agreement Prospectus Covering Offering up to $75 Mln Common Stock That May Be Issued From Time to Time
Express News | Vivani Medical Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing
Vivani Medical: A Growth-Focused Gamble With No Dividend Payouts in Sight
Vivani Medical's Innovative Obesity Treatment Promises High Compliance and Market Growth: A Strong Buy Recommendation
Vivani Medical Inc (VANI) Reports Fourth Quarter and Full Year 2023 Financial Results
Vivani Medical Updates Investors With Informative Presentations
Vivani Medical GAAP EPS of -$0.12